TG101209newfeatured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406190
CAS#:936091-14-4
Description:TG101209 is a novel and potent JAK2 inhibitor, which induced dose- and time-dependent cytotoxicity in a variety of multiple myeloma (MM) cell lines. The induction of cytotoxicity was associated with inhibition of cell cycle progression and induction of apoptosis in myeloma cell lines and patient-derived plasma cells. Exploring the mechanism of action of TG101209 indicated downregulation of pJak2, pStat3, and Bcl-xl levels with upregulation of pErk and pAkt levels indicating cross talk between signaling pathways. TG101209 , when used in combination with the PI3K inhibitor LY294002, demonstrated synergistic cytotoxicity against myeloma cells.
Price and Availability
TG101209, purity > 98%, is in stock. The same day shipping after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 406190Name: TG101209CAS#: 936091-14-4Chemical Formula: C26H35N7O2SExact Mass: 509.25729Molecular Weight: 509.67Elemental Analysis: C, 61.27; H, 6.92; N, 19.24; O, 6.28; S, 6.29
Synonym:TG101209; TG-101209; TG 101209
IUPAC/Chemical Name:N-tert-butyl-3-(5-methyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide
InChi Key:JVDOKQYTTYUYDV-UHFFFAOYSA-N
InChi Code:InChI=1S/C26H35N7O2S/c1-19-18-27-25(29-20-9-11-22(12-10-20)33-15-13-32(5)14-16-33)30-24(19)28-21-7-6-8-23(17-21)36(34,35)31-26(2,3)4/h6-12,17-18,31H,13-16H2,1-5H3,(H2,27,28,29,30)
SMILES Code:O=S(C1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O
Technical Data
Additional Information
References
1: Sun Y, Moretti L, Giacalone NJ, Schleicher S,Speirs CK, Carbone DP, Lu B. Inhibition of JAK2 signaling by TG101209enhances radiotherapy in lung cancer models. J Thorac Oncol. 2011Apr;6(4):699-706. doi: 10.1097/JTO.0b013e31820d9d11. PubMed PMID:21325979; PubMed Central PMCID: PMC3104103.
2: Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T,Pardanani A, Tefferi A, Rajkumar SV, Kumar S. TG101209, a novel JAK2inhibitor, has significant in vitro activity in multiple myeloma anddisplays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol.2010 Sep;85(9):675-86. doi: 10.1002/ajh.21785. PubMed PMID: 20652971;PubMed Central PMCID: PMC2940994.
3: Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A,Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P,Levine RL, Bhalla KN. Cotreatment with panobinostat and JAK2 inhibitorTG101209 attenuates JAK2V617F levels and signaling and exertssynergistic cytotoxic effects against human myeloproliferativeneoplastic cells. Blood. 2009 Dec 3;114(24):5024-33. doi:10.1182/blood-2009-05-222133. Epub 2009 Oct 14. PubMed PMID: 19828702;PubMed Central PMCID: PMC2788976.
4: Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, FinkeC, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, asmall molecule JAK2-selective kinase inhibitor potently inhibitsmyeloproliferative disorder-associated JAK2V617F and MPLW515L/Kmutations. Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31. PubMedPMID: 17541402.
我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心，密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向，不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是：建成全球最大的小分子抗癌药库 ，品种最多最全、质量最好最可靠。美帝药库的宗旨是：客户第一；质量第一；信誉第一；创新第一。
